Search results
Results from the WOW.Com Content Network
GSK reported second-quarter core earnings per share (EPS) of 43.4 pence on sales of 7.88 billion pounds, topping analysts' average forecasts of 38.9 pence and 7.51 billion pounds respectively ...
The London-listed drugmaker said it now expects a rise of 8% to 10% in annual adjusted earnings per share, up from the 6%-9% growth previously forecast. It also expects its 2024 sales to rise in ...
After sustaining an uptrend on the markets since bottoming in February, GlaxoSmithKline (NYSE:GSK) still has an attractive profile for income and value investors. The stock’s rock-solid dividend ...
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
GSK now expects annual adjusted earnings per share to rise between 17% and 20%, excluding the effect of currency swings, up from 14% to 17% growth previously forecast.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
GSK forecasts Arexvy will reach peak annual sales of more than 3 billion pounds ($3.79 billion). "We believe consensus Arexvy forecasts may now be lowered to reflect a smaller eligible US patient ...